Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects Academic Article uri icon

Overview

MeSH Major

  • Gene Expression Regulation, Neoplastic
  • MicroRNAs
  • Multiple Myeloma
  • Plasma Cells
  • RNA, Messenger

abstract

  • Affected mutation carriers with CTLA-4 insufficiency can present in any medical specialty. Family members should be counseled because disease manifestation can occur as late as 50 years of age. EBV- and cytomegalovirus-associated complications must be closely monitored. Treatment interventions should be coordinated in clinical trials.

authors

publication date

  • January 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2018.02.055

PubMed ID

  • 29729943

Additional Document Info